These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15094965)

  • 1. Rosiglitazone and heart failure: long-term vigilance.
    Singh N
    J Cardiovasc Pharmacol Ther; 2004 Mar; 9(1):21-5. PubMed ID: 15094965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 4. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
    Wang F; Vergara C; Carabino J; Desilets A; Vasquez R
    Am J Health Syst Pharm; 2004 Aug; 61(15):1604-8. PubMed ID: 15372837
    [No Abstract]   [Full Text] [Related]  

  • 6. Thiazolidinedione-induced congestive heart failure.
    Cheng AY; Fantus IG
    Ann Pharmacother; 2004 May; 38(5):817-20. PubMed ID: 15039476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 9. Thiazolidinedione-associated congestive heart failure and pulmonary edema.
    Mikhail NE; Wali S; Cope D
    Mayo Clin Proc; 2004 Apr; 79(4):571-2; author reply 575-7. PubMed ID: 15065626
    [No Abstract]   [Full Text] [Related]  

  • 10. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review.
    Page RL; Gozansky WS; Ruscin JM
    Pharmacotherapy; 2003 Jul; 23(7):945-54. PubMed ID: 12885108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
    Mudaliar S; Chang AR; Henry RR
    Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
    Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
    JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. After avandia: the use of antidiabetic drugs in patients with heart failure.
    Khalaf KI; Taegtmeyer H
    Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
    Marceille JR; Goins JA; Soni R; Biery JC; Lee TA
    Pharmacotherapy; 2004 Oct; 24(10):1317-22. PubMed ID: 15628829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?
    Baskin S; Neher JO; Dodson S; Hoffman R
    J Fam Pract; 2005 Aug; 54(8):723-4. PubMed ID: 16061064
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime.
    Leier CV; Haas GJ
    J Am Coll Cardiol; 2007 Jul; 50(1):37-9. PubMed ID: 17601543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.